A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
Public ClinicalTrials.gov record NCT03417102. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX
Study identification
- NCT ID
- NCT03417102
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- fitusiran Drug
- Bypassing agents Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 13, 2018
- Primary completion
- Nov 24, 2020
- Completion
- Jun 22, 2021
- Last update posted
- Mar 27, 2022
2018 – 2021
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 0117 | Phoenix | Arizona | 85016 | — |
| Investigational Site Number 0139 | Los Angeles | California | 90027 | — |
| Investigational Site Number 0135 | Orange | California | 92868 | — |
| Investigational Site Number 0137 | San Diego | California | 92123 | — |
| Investigational Site Number 0128 | Gainesville | Florida | 32610 | — |
| Investigational Site Number 0115 | Jacksonville | Florida | 32207 | — |
| Investigational Site Number 0105 | Miami | Florida | 33136 | — |
| Investigational Site Number 0103 | Tampa | Florida | 33607 | — |
| Investigational Site Number 0119 | New Orleans | Louisiana | 70112 | — |
| Investigational Site Number 0136 | Baltimore | Maryland | 21205 | — |
| Investigational Site Number 0111 | Las Vegas | Nevada | 89135 | — |
| Investigational Site Number 0104 | Philadelphia | Pennsylvania | 19104-5127 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03417102, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03417102 live on ClinicalTrials.gov.